Translate page

Please find below a selection of interesting articles on CML from peer-reviewed journals. Recent publications include:

Clinical papers

Scientific papers

Pediatric papers

Click here to see summaries of key CML publications provided to you as a special service by the iCMLf in partnership with Springer Healthcare IME

More CML Publications 2021

Clinical Publications Scientific Publications
April 2021
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib
Morita K et al. Cancer, April 2021 (epub ahead of print)
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
Hsieh YC et al. Leukemia, April 2021
(epub ahead of print) – open access publication
Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population based study
Jamy O et al. Am J Hematol, April 2021
(epub ahead of print) - open access publication
Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy
Schoepf AM et al. Eur J Med Chem, April 2021
– open access publication
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial
Kim DDH et al. Br J Haematol, April 2021
(epub ahead of print)
An aging mouse model of human chronic myeloid leukemia
Hao T et al. Oncogene, April 2021 (epub ahead of print)
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial
Chuah C et al. Int J Hematol, April 2021
(epub ahead of print)
Repositioning antispasmodic drug papaverine for the treatment of chronic myeloid leukemia
Parcha PK et al. Pharmacol Rep, April 2021
Bosutinib-related pleural effusion in patients with chronic myeloid leukemia
Yüzbasloglu MB and Eskazan AE. Expert Opin Drug Saf, April 2021
The regulation of bcr-abl in hypoxia is through the mTOR pathway
Clapper E et al. Leuk Lymphoma, April 2021
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up
Scalzulli E et al. Leuk Lymphoma, April 2021
Leukemic stem cells shall be searched in the bone marrow before tyrosine kinase inhibitor-discontinuation in chronic myeloid leukemia
Ilhan O et al. Int J Lab Hematol, April 2021 (epub ahead of print)
When to stop TKIs in patients with chronic myeloid leukemia and how to follow them subsequently
Cerveira N et al. Curr Treat Options Oncol, April 2021
Rare monosomy 7 and deletion 7p at diagnosis of chronic myeloid leukemia in accelerated phase
Alswied A et al. Cancer Genet, April 2021
Interventions to improve adherence to tyrosine kinase inhibitors in chronic myeloid leukemia: A systematic review
Heiney SP et al. Am J Clin Oncol, April 2021
(epub ahead of print)
 
March 2021
Dosing strategies for improving the risk-benefit profile of ponatinib in patients with chronic myeloid leukemia in chronic phase
Castagnetti F et al. Front Oncol, March 2021
– open access publication
Targeting chronic myeloid leukemia stem/progenitor cells using Venetoclax-loaded immunoliposome
Houshmand M et al Cancers(Basel), March 2021
– open access publication
Third-line therapy for chronic myeloid leukemia: Current status and future directions
Cortes J and Lang F. J Hematol Oncol, March 2021 – open access publication
Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study
Ottmann OG et al. Leuk Lymphoma, March 2021 
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
Radich JP et al. Leukemia, March 2021
(epub ahead of print)
– open access publication
Treatment-free remission and immunity in chronic myeloid leukemia
Ureshino H. Int J Hematol, March 2021
(epub ahead of print
Asessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
Schäfer V et al. J Cancer Res Clin Oncol, March 2021 (epub ahead of print)
– open access publication
New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism
Naka K. Int J Hematol, March 2021
(epub ahead of print
Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates
Atallah EL et al. Leuk Lymphoma, March 2021
(epub ahead of print)
Efficiency of nilotinib to target chronic-phase chronic myeloid leukaemia primary mature CD34- and immature CD34+ cells
Berger MG et al. Sci Rep, March 2021
– open access publication 

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
Martínez-López J et al. Leuk Lymphoma, March 2021 (epub ahead of print)

The discovery of novel BCR-ABL tyrosine kinase inhibitors using a pharmacophore modelling and virtual screening approach
Huang TT et al. Front Cell Dev Biol, March 2021 – open access publication 
I rock the boat? When to stop TKI’s in CML?
Nazha A. Blood, March 2021
Discovery of a novel CIP2A variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias
Makela E et al. Clin Cancer Res, March 2021
(epub ahead of print)
– open access publication 
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience
Pepe S et al. Leuk Lymphoma, March 2021
(epub ahead of print)
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogeneic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B
Bencome-Alvarez AE, Oncogene, March 2021
(epub ahead of print)
– open access publication
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world setting in France: The POST-PACE study
Etienne G et al. Leuk Res, March 2021 (epub ahead of print)

Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of CML progression
Sloma I et al. Haematologica, March 2021
– open access publication

Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
Scalzulli E et al. Ann Hematol, March 2021
(epub ahead of print)

 
arly BCR-ABL kinetics are predictive of subsequent achievement of treatment-free-remission in CML
Shanmunagathan N et al. Blood, March 2021 
 
February 2021
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKI’s: First interim analysis of OPTkIMA study
Malagola M et al. Cancer Med, February 2021
(epub ahead of print)
- open access publication
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression
Clark RE et al. Blood Adv, February 2021
- open access publication
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR – final report from AFTER-SKI
Richter J et al. Leukemia, February 2021
(epub ahead of print)
– open access publication
Eradicating residual chronic myeloid leukemia: basic research lost in translation
Zhao H and Deininger M. Lancet Haematol, February 2021
Mortality rates in patients with chronic myeloid leukemia in chronic phase with frontline second generation kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)
Breccia M et al. Ann Hematol, February 2021
Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFTM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib
Hrdinova T et al. Int J Oncol, February 2021
Dose-optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: A new therapeutic challenge
Iurlo A et al. J Clin Med, February 2021 – open access publication
 

Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells
Ozkan T et al. Leuk Res, February 2021
(epub ahead of print)

Bosutinib in the real-life treatment of chronic myeloid leukemia patients >65 years resistant/intolerant to previous tyrosine-kinase inhibitors
Latagliata R et al. Hematol Oncol, February 2021
(epub ahead of print)
Circulating miR-1461 expression to imatinib in adult chronic myeloid leukemia
Habib EM et al. J Investig Med, February 2021
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Garcia-Gutiérrez V et al. Blood Cancer J, February 2021
– open access publication
Future approaches for treating chronic myeloid leukemia: CRISP therapy
Vuelta E et al. Biology(Basel), February 2021
– open access publication

MR4 log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial
Seguro FS et al. Leuk Res, February 2021

Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells
Yahata T et al. Haematologica, February 2021
– open access publication
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Efficace F et al. Expert Rev Hematol, February 2021
(epub ahead of print)
Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: is there a correlation?
Frikha R et al. J Oncol Pharm Pract, February 2021
(epub ahead of print)
ong-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy
Cortes JE et al. Eur J Haematol, February 2021
(epub ahead of print
The prognostic importance of BCR-ABL transcripts in chronic myeloid leukemia: A systematic review and meta-analysis
Ghalesardi OK et al. Leuk Res, February 2021
  Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)
Lu T et al. Eur J Pharmacol, February 2021
(epub ahead of print)
January 2021
Clinical outcomes of patients with chronic myeloid leukemia with concurrent core binding factor rearrangement and Philadelphia chromosome
Morita K et al. Clin Lymphoma Myeloma Leuk,
January 2021 (epub ahead of print)
The giant HECT E3 ubiquitin ligase HERC1 is aberrantly expressed in myeloid related disorders and it is a novel BCR-ABL1 binding partner
Ali MS et al. Cancers(Basel), January 2021
– open access publication 
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed CML in chronic phase: ENESTnd 10-year analysis
Kantarjian HM et al. Leukemia, January 2021
(epub ahead of print) – open access publication  
Genetic screening for potential new targets in chronic myeloid leukemia based on Drosophia Transgenic for human BCR-ABL
Lo Iacono M et al. Cancers(Basel), January 2021
– open access publication 
ILong-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukemia: results from the French SPIRIT phase III randomised trial
Guilhot F et al. Leukemia, January 2021
(epub ehead of print)
The quiescent fraction of chronic myeloid leukemia stem cells depends on BMPR1B, STAT3, and BMP4-niche signals to persistent in patients in remission
Jeanpierre S et al. Haematologica, January 2021
– open access publication 
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?
Colafigli G et al. Crit Rev Oncol Hematol, January 2021
HLA polymorphis are associated with treatment-free remission following discontinuation of TKI’s in CML
Ureshino H et al. Mol Cancer Ther, January 2021 
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia in patients treated with nilotinib
Caocci G et al. Ann Hematol, January 2021
(epub ahead of print)
Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTor pathway in combination with TKIs: A review
Singh P et al. Med Oncol, January 2021
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data
Gambarcoti-Passerini C et al. Eur J Haematol, January 2021 – open access publication
The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration
Ito F et al. Int J Hematol, January 2021 
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real-life
Santoleri F et al. Curr Med Res Opin, January 2021
(epub ahead of print)
NT157, an IGF1R-IRS1/2 inhibitor exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia
Scopim-Ribeiro R et al. Invest New Drugs, January 2021 (epub ahead of print)
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukemia in the United Kingdom: the UK TARGET CML study
Milojkociv D et al. Br J Haematol, January 2021
– open access publication


BCR-ABL kinase domain mutation analysis by Next Generation Sequencing detected additional mutations in CML patients with suboptimal response to Nilotinib
Benjamin ESB et al. Leuk Lymphoma, January 2021
(epub ehead of print)
 


CML Publications 2014-2020

Access 2020 CML publications here
Access 2019 CML publications here
Access 2018 CML publications here
Access 2017 CML publications here
Access 2016 CML publications here
Access 2015 CML publications here
Access 2014 CML publications here


Would you like to suggest an interesting paper or article? >> Please provide us with the details here and we will be happy to review your suggestion!

Search for more publications on CML at PubMed.gov